Tiêu chuẩn chứng nhận: Đạt tiêu chuẩn EP
Tên IUPAC: (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;hydrochloride
Số EC: 813-550-9
Khối lượng phân tử: 443.77
Công thức hoá học: C₁₆H₁₆ClF₆N₅O
Số CAS: 486459-71-6
Tình trạng pháp lý: Tình trạng thương mại hóa; dạng đa hình Form III
Ứng dụng: Chất ức chế DPP-4 đường uống; hỗ trợ chế độ ăn/tập luyện để kiểm soát đường huyết ở đái tháo đường type 2
Status: Commercial
Therapeutic cat.: Diabetics
Polymorphic form: Form III

Thông tin khác

Mô tả thêm:

Established in 1935 and based in the Greater Poland Voivodeship, Polpharma is a manufacturer and service provider of active pharmaceutical ingredients spanning prophylactic biological products, central nervous system drugs, cardiovascular system drugs and related APIs, offering CDMO contract manufacturing to markets across North America, Latin America, Western and Eastern Europe, Australasia, Asia, the Middle East and Africa. Drawing on 75 years of experience in the API business, Polpharma API covers the full value chain from R&D through production and supply chain management to project management, operating from a European base with R&D and two manufacturing plants, and specializes in high-potency APIs (OEB 5&6), high-potency ADC payloads, advanced linker technologies, customizable ADC development solutions, cryogenic reactions and oligonucleotides. The company is recognized for international certification, an experienced R&D team, strong reputation, high-quality service and a genuinely global market presence.